The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of ...
Zacks Investment Research on MSN2d
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia StudyEli Lilly LLY and partner Incyte INCY announced that a late-stage study evaluating oral baricitinib in adolescent patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback